AbbVie (ABBV) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABBV Analyst Ratings

Strong Buy

19 Buy

4 Hold

0 Sell

Based on 23 analysts giving stock ratings to

AbbVie

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABBV Stock 12 Month Forecast

Average Price Target

$4,748.87

▲(6.93% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $4,748.87 with a high forecast of $5,321.67 and a low forecast of $3,801.19. The average price target represents a 6.93% change from the last price of $4,441.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3665":"$3,665","5322":"$5,322","4079.25":"$4,079.3","4493.5":"$4,493.5","4907.75":"$4,907.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5321.66509035,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.32K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4748.872113127143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.75K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3801.18935025,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.80K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3665,4079.25,4493.5,4907.75,5322],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4386,4457.974237719231,4529.948475438461,4601.922713157693,4673.896950876923,4745.871188596154,4817.845426315384,4889.819664034616,4961.7939017538465,5033.768139473077,5105.742377192308,5177.716614911539,5249.69085263077,{"y":5321.66509035,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4386,4413.913239471319,4441.826478942638,4469.739718413956,4497.652957885275,4525.566197356594,4553.479436827913,4581.3926762992305,4609.305915770549,4637.219155241868,4665.132394713187,4693.045634184506,4720.958873655824,{"y":4748.872113127143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4386,4341.014565403846,4296.029130807692,4251.043696211538,4206.058261615384,4161.072827019231,4116.087392423077,4071.1019578269234,4026.1165232307694,3981.1310886346155,3936.1456540384615,3891.160219442308,3846.174784846154,{"y":3801.18935025,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3790.115,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4346.093,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3985.361,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4014.666,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4014.245,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3788.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3986.136,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3790.974,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3673.317,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3666.365,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4372.052,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4385,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4386,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$5,322

Average Price Target$4,749

Lowest Price Target$3,801

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rajesh Kumar

HSBC

$5,068.25→$5,321.67

Buy

19.83%

Upside

Reiterated

09/10/26

AbbVie price target raised to $315 from $300 at HSBCAbbVie price target raised to $315 from $300 at HSBC

Jason Gerberry

Bank of America Securities

$4,764.16

Buy

7.28%

Upside

Reiterated

09/08/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Royalty Pharma (NASDAQ: RPRX) and Summit Therapeutics (NASDAQ: SMMT)

Geoff Meacham

Citi

$4,392.49

Hold

-1.09%

Downside

Reiterated

09/04/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Ionis Pharmaceuticals (NASDAQ: IONS) and AbbVie (NYSE: ABBV)

William Katz

TD Cowen

$4,730.37

Buy

6.52%

Upside

Reiterated

09/04/26

Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)

Louise Chen

Scotiabank

$4,730.37

Buy

6.52%

Upside

Reiterated

09/04/26

Scotiabank Remains a Buy on AbbVie (ABBV)

Evan Seigerman

BMO Capital

$5,068.25

Buy

14.12%

Upside

Reiterated

09/03/26

Analysts Are Bullish on These Healthcare Stocks: Eledon Pharmaceuticals (ELDN), AbbVie (ABBV)

David Amsellem

Piper Sandler

$5,034.46→$5,118.93

Buy

15.27%

Upside

Reiterated

08/20/26

AbbVie price target raised to $303 from $298 at Piper SandlerAbbVie price target raised to $303 from $298 at Piper Sandler

Mohit Bansal

Wells Fargo

$4,983.78→$5,068.25

Buy

14.12%

Upside

Assigned

08/17/26

AbbVie (ABBV) Receives a Buy from Wells Fargo

Alexandria Hammond

Wolfe Research

$5,068.25

Buy

14.12%

Upside

Upgraded

08/13/26

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (NASDAQ: LQDA), AbbVie (NYSE: ABBV) and Establishment Labs Holdings (NASDAQ: ESTA)

Emily Field

Barclays

$5,068.25

Buy

14.12%

Upside

Reiterated

08/11/26

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), AbbVie (NYSE: ABBV) and Legend Biotech (NASDAQ: LEGN)

Gavin Clark-Gartner

Evercore ISI

$4,155.97→$4,392.49

Buy

-1.09%

Downside

Assigned

08/10/26

AbbVie price target raised to $260 from $246 at Evercore ISIAbbVie price target raised to $260 from $246 at Evercore ISI

Hans Engel

Erste Group

―

Buy

―

Upgraded

08/05/26

AbbVie upgraded to Buy from Hold at Erste GroupAbbVie upgraded to Buy from Hold at Erste Group

Luisa Hector

Berenberg Bank

$4,645.9

Buy

4.61%

Upside

Reiterated

08/05/26

AbbVie (ABBV) Gets a Buy from Berenberg Bank

Vamil Divan

Guggenheim

$4,409.38→$4,865.52

Buy

9.56%

Upside

Reiterated

08/03/26

Analysts' Top Healthcare Picks: Oric Pharmaceuticals (ORIC), AbbVie (ABBV)

Terence Flynn

Morgan Stanley

$4,696.58→$5,000.68

Buy

12.60%

Upside

Assigned

08/03/26

AbbVie price target raised to $296 from $278 at Morgan StanleyAbbVie price target raised to $296 from $278 at Morgan Stanley

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rajesh Kumar

HSBC

$5,068.25→$5,321.67

Buy

19.83%

Upside

Reiterated

09/10/26

AbbVie price target raised to $315 from $300 at HSBCAbbVie price target raised to $315 from $300 at HSBC

Jason Gerberry

Bank of America Securities

$4,764.16

Buy

7.28%

Upside

Reiterated

09/08/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Royalty Pharma (NASDAQ: RPRX) and Summit Therapeutics (NASDAQ: SMMT)

Geoff Meacham

Citi

$4,392.49

Hold

-1.09%

Downside

Reiterated

09/04/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Ionis Pharmaceuticals (NASDAQ: IONS) and AbbVie (NYSE: ABBV)

William Katz

TD Cowen

$4,730.37

Buy

6.52%

Upside

Reiterated

09/04/26

Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)

Louise Chen

Scotiabank

$4,730.37

Buy

6.52%

Upside

Reiterated

09/04/26

Scotiabank Remains a Buy on AbbVie (ABBV)

Evan Seigerman

BMO Capital

$5,068.25

Buy

14.12%

Upside

Reiterated

09/03/26

Analysts Are Bullish on These Healthcare Stocks: Eledon Pharmaceuticals (ELDN), AbbVie (ABBV)

David Amsellem

Piper Sandler

$5,034.46→$5,118.93

Buy

15.27%

Upside

Reiterated

08/20/26

AbbVie price target raised to $303 from $298 at Piper SandlerAbbVie price target raised to $303 from $298 at Piper Sandler

Mohit Bansal

Wells Fargo

$4,983.78→$5,068.25

Buy

14.12%

Upside

Assigned

08/17/26

AbbVie (ABBV) Receives a Buy from Wells Fargo

Alexandria Hammond

Wolfe Research

$5,068.25

Buy

14.12%

Upside

Upgraded

08/13/26

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (NASDAQ: LQDA), AbbVie (NYSE: ABBV) and Establishment Labs Holdings (NASDAQ: ESTA)

Emily Field

Barclays

$5,068.25

Buy

14.12%

Upside

Reiterated

08/11/26

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), AbbVie (NYSE: ABBV) and Legend Biotech (NASDAQ: LEGN)

Gavin Clark-Gartner

Evercore ISI

$4,155.97→$4,392.49

Buy

-1.09%

Downside

Assigned

08/10/26

AbbVie price target raised to $260 from $246 at Evercore ISIAbbVie price target raised to $260 from $246 at Evercore ISI

Hans Engel

Erste Group

―

Buy

―

Upgraded

08/05/26

AbbVie upgraded to Buy from Hold at Erste GroupAbbVie upgraded to Buy from Hold at Erste Group

Luisa Hector

Berenberg Bank

$4,645.9

Buy

4.61%

Upside

Reiterated

08/05/26

AbbVie (ABBV) Gets a Buy from Berenberg Bank

Vamil Divan

Guggenheim

$4,409.38→$4,865.52

Buy

9.56%

Upside

Reiterated

08/03/26

Analysts' Top Healthcare Picks: Oric Pharmaceuticals (ORIC), AbbVie (ABBV)

Terence Flynn

Morgan Stanley

$4,696.58→$5,000.68

Buy

12.60%

Upside

Assigned

08/03/26

AbbVie price target raised to $296 from $278 at Morgan StanleyAbbVie price target raised to $296 from $278 at Morgan Stanley

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

SNDXSyndax Pharmaceuticals

PTGXProtagonist Therapeutics

ONCBeOne Medicines

HITIHigh Tide

IRTCIrhythm Technologies

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

3 Months

Chris SchottJ.P. Morgan

Success Rate

24/32 ratings generated profit

Average Return

+7.96%

Copying Chris Schott's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +7.96% per trade.

1 Year

Mohit BansalWells Fargo

Success Rate

31/31 ratings generated profit

Average Return

+19.81%

Copying Mohit Bansal's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +19.81% per trade.

2 Years

Mohit BansalWells Fargo

Success Rate

31/31 ratings generated profit

Average Return

+33.89%

Copying Mohit Bansal's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +33.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABBV Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABBV has received 37 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. ABBV average Analyst price target in the past 3 months is 4,748.87.

Each month's total comprises the sum of three months' worth of ratings.

ABBV Financial Forecast

ABBV Earnings Forecast

Next quarter’s earnings estimate for ABBV is $65.56 with a range of $65.19 to $67.06. The previous quarter’s EPS was $61.96. ABBV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.

ABBV Sales Forecast

Next quarter’s sales forecast for ABBV is $293.90B with a range of $291.97B to $296.71B. The previous quarter’s sales results were $288.43B. ABBV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.

ABBV Stock Forecast FAQ

What is MX:ABBV’s average 12-month price target, according to analysts?

Based on analyst ratings, AbbVie’s 12-month average price target is 4,748.87.

What is MX:ABBV’s upside potential, based on the analysts’ average price target?

AbbVie has 6.93% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AbbVie a Buy, Sell or Hold?

AbbVie has a consensus rating of Strong Buy, which is based on 19 buy ratings, 4 hold ratings and 0 sell ratings.

What is AbbVie’s share price target?

The average share price target for AbbVie is 4,748.87. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $5,321.67 ,and the lowest forecast is $3,801.19. The average share price target represents 6.93% Increase from the current price of $4,441.

What do analysts say about AbbVie?

AbbVie’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of AbbVie?

To buy shares of MX:ABBV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AbbVie (ABBV) Stock Forecast & Price Target

ABBV Analyst Ratings

ABBV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbbVie

ABBV Analyst Recommendation Trends

ABBV Financial Forecast

ABBV Earnings Forecast

ABBV Sales Forecast

ABBV Stock Forecast FAQ

Detailed List of Analyst Forecasts